Immunotherapy with chemotherapy for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with thoracic esophageal squamous cell carcinoma (cancer of the food tube) that hasn't spread to distant organs, but is borderline resectable (difficult to remove but possibly removable)
- Never received chemotherapy or radiation therapy before
- Good overall health status (able to care for yourself with minimal help)
- Blood counts, liver, and kidney function within acceptable ranges (tested within 7 days)
- No severe complications like active bleeding, perforation, blockage, or high fever
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug called adebrelimab before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes for people with locally advanced disease.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This trial tests adding an immunotherapy drug called adebrelimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination shrinks tumors more and improves outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.